학술논문
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Document Type
Journal Article
Author
Source
Subject
*CANCER treatment
*SMALL cell lung cancer
*LUNG cancer patients
*PACLITAXEL
*TOMOGRAPHY
*ANTINEOPLASTIC agents
*MAGNETIC resonance imaging
TUMOR growth prevention
*
*
*
*
*
*
Language
ISSN
0007-0920
Abstract
ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA). This randomised phase II study evaluated ASA404 plus standard therapy of carboplatin and paclitaxel in patients with histologically confirmed stage IIIb or IV non-small cell lung cancer (NSCLC) not previously treated with chemotherapy. Patients were randomised to receive